Abstract 75P
Background
Adebrelimab is a novel humanised IgG4 monoclonal antibody against PD-L1, indicated for the first-line treatment of adult Patients with ES-SCLC in China. A registry study was conducted with the use of disease-specific database of lung cancer, at 21 Centres in Jiangsu, China. Here, we report results of Cohort ADBL-LC-001: the efficacy and safety of adebrelimab in the first-line treatment of patients with SCLC.
Methods
We prospectively collected medical records from patients with SCLC, who initiated first-line treatment with adebrelimab. Primary endpoint is progression-free survival (PFS) by RECIST 1.1, secondary endpoints included overall survival (OS), objective response rate (ORR) , disease control rate (DCR) and safety.
Results
Between March 2023 and March 2024, 143 patients were included, the median follow-up was 10.3 months. Overall, 114(80%) patients were ES-SCLC and 29(80%) LS-SCLC, median age was 67 years (rang, 34-84), and most patients were ≥65 years (62%), male (78%), with an ECOG score of one (90%). 29 (25%) patients with ES-SCLC had liver metastases, 23 (20%) had Brain metastases. In the group ES-SCLC, mOS was 12.4 months (95% CI, 10.0-14.9) and mPFS was 6.7 months (95% CI, 5.3-7.7), the ORR, DCR was 34.2%, 85.1%, respectively. In the group LS-SCLC, mOS was 15.4 months (95% CI, 13.7-NA) and mPFS was 14.6 months (95% CI, 13.4-15.4), the ORR, DCR was 51.7%, 96.6%, respectively. In the IIT population, TEAEs occurred in 136 (95.1%) patients, grade 3 or worse TEAEs occurred in 29 (20.3%) patients. The most common grade ≥ 3 TEAEs were neutrophil count decreased (8.4%), lymphocyte count decreased (5.6%), anemia (3.5%), white blood cell decreased (2.8%), γ-glutamyltransferase increased (2.8%). The safety profile was generally manageable, without any unexpected adverse events. Table: 75P
The most common adverse events (incidence>20%)
| AEs, n(%) | ES-SCLC(N=114) | LS-SCLC(N=29) | Total(N=143) | |||
| Any gade | Gade ≥ 3 | Any gade | Gade ≥ 3 | Any gade | Gade ≥ 3 | |
| All gade | 110 (96.5%) | 26 (22.8%) | 26 (89.7%) | 3 (10.3%) | 136 (95.1%) | 29 (20.3%) |
| Anemia | 74 (64.9%) | 4 (3.5%) | 21 (72.4%) | 1 (3.5%) | 95 (66.4%) | 5 (3.5%) |
| Lymphocyte count decreased | 51 (44.7%) | 8 (7.0%) | 15 (51.7%) | 0 | 66 (46.2%) | 8 (5.6%) |
| Hypoalbuminemia | 51 (44.7%) | 1 (0.8%) | 7 (24.1%) | 0 | 58 (40.6%) | 1 (0.7%) |
| White blood cell decreased | 35 (30.7%) | 4 (3.5%) | 5 (17.2%) | 0 | 40 (28.0%) | 4 (2.8%) |
| Nausea | 29 (25.4%) | 0 | 10 (34.5%) | 0 | 39 (27.3%) | 0 |
| Neutrophil count decreased | 29 (25.4%) | 11 (9.7%) | 9 (31.0%) | 1 (3.5%) | 36 (25.2%) | 12 (8.4%) |
| Fever | 13 (11.4%) | 0 | 10 (34.5%) | 0 | 13 (9.1%) | 0 |
Conclusions
This Real-world data verified the efficacy and safety of adebrelimab in the first-line treatment of patients with SCLC.
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceutical Co. LTD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
226P - Profiling of gastric adenocarcinomas from EU and LATAM countries identifies distinct tumor immune subgroups and a central role of the tumor microbiome in shaping the immune microenvironment
Presenter: Manuel Cabeza Segura
Session: Poster Display session
228P - Modulating mitochondrial dynamics in TAMs to enhance anti-tumor immunity
Presenter: Pu-ste Liu
Session: Poster Display session
Resources:
Abstract
229P - Investigation of the effects of long-noncoding RNA NRAV on interferon response in melanoma
Presenter: Kadir Durmus
Session: Poster Display session
230P - Deciphering the mechanism of immunosuppressive activity of acetaminophen in the context of cancer immunotherapy
Presenter: Jeanne Lena
Session: Poster Display session
231P - The impact of calcitriol and tacalcitol on the Th17 lymphocytes in breast cancer
Presenter: Beata Filip-Psurska
Session: Poster Display session